Revealing detrimental effects of various DC electrical energy conditions on different multidrug resistant bacteria: a comprehensive study.

Publication date: Jul 24, 2024

The arbitrary discharge of contaminated wastes, especially that encompass multidrug resistant microbes (MDR), would broaden the circle of epidemic diseases such as COVID-19, which in turn deteriorate definitely the whole socioeconomics. Therefore, the employment of electrical stimulation techniques such as direct current (DC) with low energy considers being effective tool to impede spontaneous changes in microbial genetic makeup, which increases the prevalence of MDR phenomenon. Herein, the influence of different electric energies generated by DC electric field, volts and time on MDR-bacteria that are categorized among the highly ranked nosocomial pathogens, was scrutinized. Wherein, Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus and Enterococcus faecalis were examined as paradigms of Gram-negative and Gram-positive pathogens. The results declared the significant superior antagonizing potency of electric energy in a dose-dependent modality rather than the applied volts or exposure time. Notably, the exposure of bacterial cultures to140 J inhibited the bacterial count by > 78% and the range of 47-73% for Gram-negative and Gram-positive, respectively. While the suppression in their metabolic activity assessed by > 75% and 41-68%, respectively; reflecting the capability of electrical energy to induce viable but non-culturable (VBNC) state. Similarly, the results of total protein, extracellular protein content and lactate dehydrogenase activity emphasized the cell wall deterioration and losing of cell membrane integrity. Additionally, the elevating in ROS upon DC-exposure participated in DNA fragmentation and plasmid decomposability by the range of 33-60%. Further, SEM micrographs depicted drastic morphological deformations after electrical treatment. Strikingly, DC-treatment impaired antibiotic resistance of the examined strains against several antibiotics by > 64. 2%. Generally, our comparative detailed study revealed deleterious potentiality of different DC-protocols in defeating microbial pollution, which could be invested as efficient disinfectant alternative in various sectors such as milk sterilization and wastewater purification.

Open Access PDF

Concepts Keywords
Efficient Anti-Bacterial Agents
Milk Anti-Bacterial Agents
Pathogens Electricity
Staphylococcus Enterococcus faecalis
To140 Escherichia coli
Gram-Negative Bacteria
Humans
Microbial Sensitivity Tests
Pseudomonas aeruginosa
Staphylococcus aureus

Semantics

Type Source Name
disease VO Bacteria
disease MESH COVID-19
disease VO effective
disease VO time
disease VO dose
disease VO viable
disease MESH DNA fragmentation
disease IDO antibiotic resistance
disease VO efficient
drug DRUGBANK Coenzyme M
disease MESH Infection
disease IDO host
disease IDO opportunistic pathogen
disease VO organization
disease MESH infectious diseases
disease MESH morbidity
drug DRUGBANK Water
disease VO manufacturing
disease VO storage
disease VO SrtA
drug DRUGBANK Hydrogen peroxide
disease VO effectiveness
disease IDO bactericidal
disease IDO bacteriostatic
drug DRUGBANK Trestolone
disease IDO pathogen
disease VO inactivation
disease IDO process
disease MESH death
drug DRUGBANK Copper
disease VO efficiency
disease VO protocol
disease IDO blood
disease IDO production
drug DRUGBANK Silver
disease IDO assay
drug DRUGBANK Dimethyl sulfoxide
disease VO viability
disease VO manufacturer
drug DRUGBANK Human Serum Albumin
disease VO volume
drug DRUGBANK NADH
drug DRUGBANK Monopotassium phosphate
drug DRUGBANK Nadide
drug DRUGBANK Isopropyl Alcohol
drug DRUGBANK Ethanol
drug DRUGBANK Medical air
disease VO USA
drug DRUGBANK Oxygen
drug DRUGBANK Phosphate ion
disease IDO cell
disease MESH dehydration
drug DRUGBANK Flunarizine
drug DRUGBANK Gold
disease IDO susceptibility
drug DRUGBANK Ceftazidime
drug DRUGBANK Ciprofloxacin
drug DRUGBANK Norfloxacin
drug DRUGBANK Amikacin
drug DRUGBANK Cefepime
drug DRUGBANK Imipenem
drug DRUGBANK Meropenem
drug DRUGBANK Ofloxacin
drug DRUGBANK Tigecycline
drug DRUGBANK Methylergometrine
drug DRUGBANK Rifampicin
drug DRUGBANK Vancomycin
drug DRUGBANK Nitrofurantoin
drug DRUGBANK Doxycycline
disease VO ANOVA
disease VO population
drug DRUGBANK Albendazole
disease MESH oxidative stress
drug DRUGBANK Erythromycin
pathway REACTOME Metabolism
disease MESH endocarditis
disease MESH bacteremia
disease MESH urinary tract infections
disease MESH pneumonia
disease MESH osteomyelitis
disease MESH intra abdominal infections
disease MESH wound infections
drug DRUGBANK Chlorine
drug DRUGBANK Hypochlorite
disease MESH water quality
drug DRUGBANK Ozone
disease VO ProHIBiT
drug DRUGBANK ATP
disease IDO replication
disease VO Catalase
drug DRUGBANK Activated charcoal
disease IDO commensal
drug DRUGBANK Barium
drug DRUGBANK Iron
disease VO NAP
drug DRUGBANK Biotin
drug DRUGBANK Ditiocarb
disease MESH liver cancer
drug DRUGBANK Meticillin
drug DRUGBANK Nonoxynol-9
disease IDO virulence
drug DRUGBANK Zinc oxide
drug DRUGBANK Chlorhexidine
drug DRUGBANK Phenol

Original Article

(Visited 4 times, 1 visits today)